Retatrutide vs Tirzepatide (Mounjaro): 28.7% vs 22.5% (2026 Data) Phase 3 trial comparison: Retatrutide 28.7% weight loss vs Tirzepatide 22.5%
This contrasts sharply with previous studies, which have shown persistence rates as low as 42% at 12 weeks and 33% at 24 weeks
Pharmacoepidemiologists and endocrinologists have raised concern that the rapid increase in prescriptions for GLP-1s has, in some cases, not kept up with clinical and regulatory pathways to ensure safety and efficacy
It catalyzes the dismutation of O2to O2 and H2O
Other possible interactions include painkillers, blood pressure medications (beta-blockers), certain antibiotics, antidepressants, psychiatric medications, antiepileptic drugs, corticosteroids, antiviral drugs, immunosuppressants, thyroid medications, and anticoagulants
This may be especially beneficial for individuals focused on longevity, athletic performance, or recovery from burnout